Equities
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)1.40
  • Today's Change0.045 / 3.33%
  • Shares traded2.75m
  • 1 Year change+292.36%
  • Beta2.9084
Data delayed at least 20 minutes, as of Nov 08 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Mesoblast Ltd's revenues fell -21.32% from 7.50m to 5.90m. a loss of 81.89m to a larger loss of 87.96m.
Gross margin-166.30%
Net profit margin-1,490.28%
Operating margin-1,173.11%
Return on assets-13.14%
Return on equity-17.91%
Return on investment-14.38%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Mesoblast Ltd fell by 8.36m. Cash Flow from Financing totalled 40.25m or 682.01% of revenues. In addition the company used 48.46m for operations while cash used for investing totalled 97.00k.
Cash flow per share-0.1264
Price/Cash flow per share--
Book value per share0.6303
Tangible book value per share-0.1252
More ▼

Balance sheet in USDView more

Mesoblast Ltd has a Debt to Total Capital ratio of 19.84%, a lower figure than the previous year's 21.22%.
Current ratio1.18
Quick ratio--
Total debt/total equity0.2476
Total debt/total capital0.1984
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.